Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 96pembrolizumab 63Cisplatin 62Cyclophosphamide 44Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 24olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × AM0010 × Gynecologic × Clear all
NCT02009449 2024-11-15

IVY

Eli Lilly and Company

Phase 1 Completed
353 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡